AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Sep 2026 07:00 AM
RNS
Trixeo approved in EU for asthma
21 Sep 2026 07:05 AM
RNS
Klygefa recommended for EU approval by CHMP
21 Sep 2026 07:00 AM
RNS
Enhertu recommended for approval in EU in early BC
18 Sep 2026 11:00 AM
RNS
Director/PDMR Shareholding
15 Sep 2026 03:05 PM
RNS
Director/PDMR Shareholding
15 Sep 2026 03:00 PM
RNS
Director/PDMR Shareholding
14 Sep 2026 07:00 AM
RNS
Update on SERENA-4 Phase III trial
08 Sep 2026 02:00 PM
RNS
Imfinzi+Imdelltra improved OS in small cell lung
07 Sep 2026 07:00 AM
RNS
Etcamah approved in the US for HR+ breast cancer
01 Sep 2026 03:05 PM
RNS
Admission of Further Securities to Trading
01 Sep 2026 03:00 PM
RNS
Total Voting Rights
01 Sep 2026 11:00 AM
RNS
Admission to Trading - €2.55 billion bond offering
01 Sep 2026 07:30 AM
RNS
Enhertu approved in EU for 1L HER2-positive mBC
01 Sep 2026 07:10 AM
RNS
Directorate change
01 Sep 2026 07:05 AM
RNS
AstraZeneca completes agreement for Zegfrovy
01 Sep 2026 07:00 AM
RNS
Tagrisso + Orpathys improved PFS in 1L EGFRm lung
27 Aug 2026 07:00 AM
RNS
Tezspire CROSSING trial met primary endpoints
25 Aug 2026 07:00 AM
RNS
AstraZeneca prices a €2.55 billion bond offering
19 Aug 2026 11:00 AM
RNS
Director/PDMR Shareholding
17 Aug 2026 07:30 AM
RNS
Enhertu improved PFS in 1L HER2m lung cancer
17 Aug 2026 07:05 AM
RNS
Update on eVOLVE-Lung02 Phase III trial
17 Aug 2026 07:00 AM
RNS
Tagrisso+Orpathys improved PFS & OS in EGFRm lung
03 Aug 2026 03:05 PM
RNS
Admission of Further Securities to Trading
03 Aug 2026 03:00 PM
RNS
Total Voting Rights
31 Jul 2026 07:30 AM
RNS
Datroway approved in EU for TNBC
27 Jul 2026 07:10 AM
RNS
Update on Ultomiris Phase III trial in HSCT-TMA
27 Jul 2026 07:05 AM
RNS
Sone-Ve improved survival in gastric cancers
27 Jul 2026 07:00 AM
RNS
Half-year Financial Report
23 Jul 2026 07:00 AM
RNS
Etcamah approved in the EU for ER+ breast cancer 
14 Jul 2026 07:00 AM
RNS
AstraZeneca licenses novel EGFR inhibitor
09 Jul 2026 07:00 AM
RNS
Update on CARDIO-TTRansform Phase III trial
01 Jul 2026 03:05 PM
RNS
Admission of Further Securities to Trading
01 Jul 2026 03:00 PM
RNS
Total Voting Rights
29 Jun 2026 07:30 AM
RNS
Enhertu approved in EU for HER2+ solid tumours
29 Jun 2026 07:00 AM
RNS
Datroway recommended for approval in EU for TNBC
15 Jun 2026 07:00 AM
RNS
Truqap approved in US for prostate cancer
01 Jun 2026 03:05 PM
RNS
Admission of Further Securities to Trading
01 Jun 2026 03:00 PM
RNS
Total Voting Rights
29 May 2026 07:00 AM
RNS
Imfinzi approved in US for early bladder cancer
27 May 2026 07:00 AM
RNS
US FDA decision date on camizestrant extended
26 May 2026 07:00 AM
RNS
Enhertu recommended in EU for HER2+ solid tumours
26 May 2026 07:00 AM
RNS
Camizestrant recommended for breast cancer in EU
26 May 2026 07:00 AM
RNS
Datroway approved in US for 1L triple-negative BC
18 May 2026 03:00 PM
RNS
Director/PDMR Shareholding
18 May 2026 07:05 AM
RNS
Enhertu approved in two HER2+ early BC settings
18 May 2026 07:00 AM
RNS
Baxfendy approved in the US for hypertension
14 May 2026 07:00 AM
RNS
Imfinzi + EV improves EFS & OS in bladder cancer
01 May 2026 03:00 PM
RNS
Total Voting Rights and Admission of Shares
01 May 2026 07:05 AM
RNS
FDA ODAC vote on camizestrant in breast cancer
01 May 2026 07:00 AM
RNS
FDA ODAC recommends Truqap in prostate cancer

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings